Abstract
Simple SummaryAs rare but life-threatening complications, respiratory–digestive tract fistulas (RDF) have a major impact on esophageal cancer patients. Furthermore, interdisciplinary treatment concepts are still evolving. This retrospective study aims to assess general strategies for RDF, especially in terms of technical and anatomical approaches. In 51 RDF patients, we proved that bilateral fistula repair and combined surgical and non-surgical intervention correlated significantly with good short- and long-term outcomes.Respiratory–digestive tract fistulas are fatal complications that occur in esophageal cancer treatment. Interdisciplinary treatment strategies are still evolving, especially in anatomical treatment stratification. Thus, this study aims to evaluate general therapeutic strategies for this rare condition. Medical records were reviewed for esophageal cancer-associated respiratory–digestive tract fistula patients treated between January 2008 and September 2021. Fistulas were classified according to being surgery- and tumor-associated. Treatment strategies, clinical success, and survival were analyzed. A total of 51 patients were identified: 28 had tumor-associated fistulas and 23 surgery-associated fistulas. Risk factors for fistula development such as radiation (OR = 0.290, p = 0.64) or stent implantation (OR = 1.917, p = 0.84) did not correlate with lack of symptom control for RDF patients. In contrast, advanced lymph node metastasis as another risk factor was associated with persistent symptoms after treatment for RDF patients (OR = 0.611, p = 0.01). Clinical success significantly correlated with bilateral fistula repair in surgery-associated fistulas (p = 0.01), while tumor-associated fistulas benefited the most from non-surgical (p = 0.04) or combined surgical and non-surgical intervention (p = 0.04) and a bilateral fistula repair (p = 0.02) in terms of overall survival. The therapeutic strategy should aim for bilateral fistula closure. A multidisciplinary, stepwise approach might have the best chance for restoration or symptom control with optimized overall survival in selected patients.
Highlights
Respiratory–digestive tract fistulas (RDF) are among the most fatal and life-threatening complications during the treatment of esophageal carcinoma (EC)
After tumor-associated RDF (T-RDF) diagnosis, survival with supportive therapy alone is reported to range between 1 and 8 weeks [1,5,22–27], which can be extended with non-surgical treatment, if clinically successful, up to 3.4–7.9 months [21,26,28,29]
surgery-associated RDF (S-RDF) had a higher share of lower tumors and esophagobronchial (EBF) rather than esophagotracheal fistula (ETF)
Summary
Respiratory–digestive tract fistulas (RDF) are among the most fatal and life-threatening complications during the treatment of esophageal carcinoma (EC). The pathological communication between the respiratory and digestive tract affects 5–22% of patients with advanced EC [1–6], potentially underestimating the de facto incidence as autopsy data have shown [6]. After tumor-associated RDF (T-RDF) diagnosis, survival with supportive therapy alone is reported to range between 1 and 8 weeks [1,5,22–27], which can be extended with non-surgical treatment, if clinically successful, up to 3.4–7.9 months [21,26,28,29]. In well-selected patients, surgical intervention has resulted in significantly longer survival of 10–105.0 months [15,30,31]. For surgery-associated RDF (S-RDF), overall mortality has been reported to range between 25.0 and 57.1%, with inconsistent results regarding surgical (17.4–100.0%) and non-surgical (25.0–28.3%) outcome [18,32,33]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
